Indica Labs LLC.

Indica Labs is a global leader in AI-powered digital pathology software and services headquartered in Albuquerque, NM. The company develops the HALO platform suite—a comprehensive digital pathology ecosystem for research, clinical diagnostics, and pharmaceutical development. HALO includes image analysis, case management, AI-driven biomarker quantification, and cloud-based collaboration tools. Key clinical products include HALO AP Dx (FDA-cleared diagnostic case management platform), HALO AP (anatomic pathology platform), and specialized AI modules for prostate adenocarcinoma detection and grading (Prostate AI), lung PD-L1 quantification (Lung PD-L1 AI), breast cancer biomarker quantification (Breast IHC AI for HER2, ER, PR, Ki67), and tissue quality assessment (Slide QC). The company also offers macrodissection AI tools for tumor content quantification in NSCLC and colorectal cancer to guide molecular testing workflows. HALO AI provides machine-learning capabilities for custom tissue and cell detection and segmentation across multiplex imaging modalities including MIBI, CODEX, and RNAscope. Services include pharma-grade image analysis outsourcing and AWS-hosted HALO Cloud deployments. With 3,000+ installations worldwide, 259+ deployments in top-20 pharma companies, and operations in 12 countries, Indica Labs serves academic medical centers, diagnostic laboratories, pharmaceutical research organizations, and clinical trial sponsors. The platform supports whole-slide imaging analysis, tissue microarray quantification, multi-omics imaging workflows, and clinical trial biomarker validation. HALO AP earned highest KLAS ratings (94.9/100) in 2026 digital pathology software benchmarking.